In Re Ribozyme Pharmaceuticals, Inc. Securities Litigation

209 F. Supp. 2d 1106, 2002 U.S. Dist. LEXIS 13210, 2002 WL 1540749
CourtDistrict Court, D. Colorado
DecidedJuly 15, 2002
Docket1:99-cv-02235
StatusPublished
Cited by68 cases

This text of 209 F. Supp. 2d 1106 (In Re Ribozyme Pharmaceuticals, Inc. Securities Litigation) is published on Counsel Stack Legal Research, covering District Court, D. Colorado primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
In Re Ribozyme Pharmaceuticals, Inc. Securities Litigation, 209 F. Supp. 2d 1106, 2002 U.S. Dist. LEXIS 13210, 2002 WL 1540749 (D. Colo. 2002).

Opinion

MEMORANDUM OPINION AND ORDER

KRIEGER, District Judge.

This matter came before me on the Defendants’ Motion for Summary Judgment and the Plaintiffs’ Motion for Partial Summary Judgment (Motions'). I reviewed the Motions, briefs and supplementary materials submitted and, after considering the parties’ oral arguments presented on May 15, 2002, rendered an oral ruling denying both Motions. This Memorandum Opinion is issued in supplementation of that ruling.

I. JURISDICTION

This Court has jurisdiction pursuant to 28 U.S.C. § 1331.

II. MATERIAL FACTS

For purposes of these Motions, the following facts are material. 1 This case in *1108 volves a class action 2 brought on behalf of all persons who purchased common stock of Ribozyme Pharmaceuticals, Inc., (“Ribo-zyme”) between the close of trading on November 15, 1999, and the close of trading on November 17, 1999. Defendant Ribozyme is a Delaware corporation with its principal executive offices in Colorado. Defendant Ralph E. Christoffersen (“Christoffersen”), a resident of Colorado, has been the Chief Executive Officer, President and Director of Ribozyme since 1992.

In collaboration with Chiron Corporation (“Chiron”), Ribozyme began developing a new drug, Angiozyme, designed to inhibit the production of a specific protein and, potentially, to restrict or halt the development or spread of certain types of cancer. On November 15, 1999, Riboyzme issued a media advisory entitled “Colorado Pharmaceutical Co., Makes Drug History,” (November 15 Media Advisory), announcing a press conference scheduled for November 17, 1999, which included the statement that “RPI CEO & President, Ralph E. Christoffersen, Ph.D., and other senior RPI staff, will explain Angiozyme and its recent history-making leap, an achievement which may be of great significance to cancer patients everywhere.”

On the following day, November 16, 1999, the price of a share of Ribozyme stock, which was traded on NASDAQ, opened at $13,625 after closing the previous night at $10.0625. The share price continued to rise, reaching a price of $22.00 within an hour and twenty-five minutes of the market opening. Then, trading of Ribozyme stock was halted and representatives of Chiron Corporation issued statements of clarification which Ribozyme followed with a press release. At the close of trading on November 16, 1999, the price of Ribozyme stock had dropped to $12.25.

This action was filed shortly thereafter, naming Ribozyme and Christofferrsen as Defendants. In it, Plaintiffs allege violations of Sections 10(b) and 20(a) of the Securities Exchange Act, claiming that the November 15 Media Advisory was a misleading statement made in connection with the purchase or sale of securities either ■with the intent to defraud or, at least, in a reckless manner. For purposes of these Motions, the parties agree that the individually named Plaintiffs relied upon the misleading statement. The parties dispute, however, whether the class Plaintiffs relied upon the market to their detriment, the detriment being the precipitous increase and subsequent drop in the price of Ribo-zyme stock as a result of the public statements made by representatives of Ribo-zyme and Chiron.

III. ISSUES PRESENTED

The parties have filed cross motions requesting summary judgment pursuant to the Federal Rules of Civil Procedure. The Plaintiffs request partial summary judgment on the issue of liability. The Defendants request summary judgment on all issues, arguing that Plaintiffs have insufficient evidence to prove the elements of scienter and reliance necessary to establish a prima facie violation of Section 10(b) of the Exchange Act. I find that there are factual issues in dispute as to the following: (1) whether the Media Advisory issued on November 15 was misleading and, *1109 if so, whether this was by intention or negligence on the part .of the Defendants; and (2) whether the Plaintiffs relied upon the market to their detriment. Therefore, the Motions are DENIED.

IV. ANALYSIS

A. The Summary Judgment Formula.

Determination of claims or defenses on their merits but without a trial is governed by Rule 56 of the Federal Rules of Civil Procedure. In this district, there is a prevalent practice of filing Rule 56 motions in almost every civil action. 3 Such motions may be intended to flush out an opponent’s case, to try to educate the judge, to knock out various legal theories premised on a single underlying fact scenario, or to tip the negotiating table. However, Rule 56 motions are not appropriate in every action. Indeed, it is the rare case where a Rule 56 motion should be filed. Proper and skillful use of Rule 56 requires counsel to engage in the same thorough legal analysis as would be required of a presentation of a claim or defense at trial. Because the inappropriate and overuse of Rule 56 motions delays the progress of civil litigation, 4 a review of the purpose and application of Rule 56 may prove helpful.

The intended purpose of Rule 56 is to facilitate the entry of a judgment without a trial. The civil legal process favors factual dispute resolution by live testimony presented at a trial; summary determination based -solely on documentary evidence short circuits that process. Therefore, under Rule 56, the fundamental issue is whether a trial is necessary. 5 A trial is necessary if there are material factual issues to be resolved.

Rule 56 expressly authorizes summary adjudication “when there is no genuine dispute as to any material fact and ... the moving party is entitled to judgment as a matter of law.” FED.R.CIV.P. 56(c). This standard requires a court to make two distinct determinations; one as a prerequisite to the other. The first determination is whether there is a genuine dispute as to any issue of material fact. 6 If there is such a dispute, the motion must be denied. Only when all material facts are undisputed can a court move to the second determination, that of applying the law to the undisputed facts to enter a judgment. 7

1. What is a Material Factual Issue?

Substantive law frames the material facts and factual issues by specifying the elements that must be proved to establish a claim or defense, setting the standard of proof and identifying the 'party with the burden of proof. 8

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
209 F. Supp. 2d 1106, 2002 U.S. Dist. LEXIS 13210, 2002 WL 1540749, Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-ribozyme-pharmaceuticals-inc-securities-litigation-cod-2002.